Estradiol (Sensitive LC-MS/MS) (E2)
Estradiol is the primary biological estrogen. In men, it is derived from peripheral aromatization of testosterone by CYP19A1 (aromatase), essential for vascular endothelial health and bone mineral density.
Standard vs. Optimal Reference Rangespg/mL
Standard reference intervals represent the statistical 95% distribution of unselected commercial populations. Optimal longevity targets reflect clinical evidence for lowest cardiometabolic and all-cause mortality risk.
Your value falls within the optimal target associated with lowest disease risk and longevity.
10 - 40 pg/mL (Male), Phase-dependent (Female)
General reference distribution across unselected commercial populations.
20 - 30 pg/mL (Male)
Concentration target associated with minimal all-cause cardiometabolic mortality.
Molecular Mechanism & Clinical Purpose
Binds nuclear estrogen receptors ER-alpha and ER-beta, regulating eNOS expression, lipid metabolism, and osteoclastic apoptosis. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) avoids immunoassay cross-reactivity with other steroids.
Differential Diagnosis
Elevated Levels (E2 High)
- •High aromatase activity in visceral adipose tissue
- •Exogenous testosterone / HCG therapy
- •Estrogen replacement therapy (females)
- •Leydig cell tumors
Low Levels (E2 Low)
- •Aromatase inhibitor therapy (Anastrozole, Letrozole)
- •Hypogonadotropic hypogonadism
- •Menopause (females)
Technical Reference & Deep Dive
Biochemistry & Enzymatic Pathways
Longevity Risk Architecture & Epidemiology
Pre-Analytical Caveats & Diagnostic Workup
Pre-Analytical Considerations:
Blood draw must occur strictly between 7:00 AM and 9:00 AM to account for steep circadian cortisol and testosterone peaks. Ensure 8 hours of restful sleep prior; night shift work or sleep deprivation severely blunts endocrine pulsatility. Discontinue biotin supplements for 72 hours before thyroid or steroid testing to prevent false immunoassay results. For reproductive hormones in premenopausal females, precisely document the day of the menstrual cycle (Day 3 for baseline follicular, Day 21 for luteal).
Reflexive Testing Protocol:
- Free Hormone Equilibrium Dialysis or LC-MS/MS assay for direct bioavailable hormone quantification
- Pituitary trophic hormone panel (TSH, LH, FSH, ACTH, Prolactin) to differentiate primary vs central secondary endocrinopathies
- Autoantibody quantification (Thyroid Peroxidase Antibodies, Thyroglobulin Antibodies, 21-Hydroxylase Antibodies)
- Pelvic, testicular, or thyroid high-resolution ultrasound imaging to assess glandular parenchymal architecture
- Dynamic endocrine stimulation testing (Cosyntropin/ACTH stimulation test, Dexamethasone suppression test, GnRH test)
Clinical Citations & Primary Literature (1)
- [1]Estrogen Action in Male Physiology and Bone Health - Endocrine Reviews (2021). PMID: 33792040
Associated Longevity Guides & Clinical Calculators
Medicine 3.0Explore comprehensive evidence-based clinical protocols, testing costs, and algorithmic calculators that incorporate Estradiol (Sensitive LC-MS/MS) (E2) into overall healthspan optimization.